238 related articles for article (PubMed ID: 24684351)
1. Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.
Davis TM
Diabetes Obes Metab; 2014 Oct; 16(10):891-9. PubMed ID: 24684351
[TBL] [Abstract][Full Text] [Related]
2. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Scheen AJ
Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
[TBL] [Abstract][Full Text] [Related]
3. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
4. An update on the 'gliptins'.
Drug Ther Bull; 2016 Dec; 54(12):138-141. PubMed ID: 27979881
[TBL] [Abstract][Full Text] [Related]
5. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
Nowicki M; Rychlik I; Haller H; Warren ML; Suchower L; Gause-Nilsson I;
Diabetes Obes Metab; 2011 Jun; 13(6):523-32. PubMed ID: 21332627
[TBL] [Abstract][Full Text] [Related]
6. Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease.
Ramirez G; Morrison AD; Bittle PA
Endocr Pract; 2013; 19(6):1025-34. PubMed ID: 23757605
[TBL] [Abstract][Full Text] [Related]
7. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
Jarvis CI; Cabrera A; Charron D
Ann Pharmacother; 2013 Nov; 47(11):1532-9. PubMed ID: 24285765
[TBL] [Abstract][Full Text] [Related]
8. [The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
Špinar J; Špinarová L; Vítovec J
Vnitr Lek; 2015 Nov; 61(11):976-83. PubMed ID: 26652787
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ
Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
Takayanagi R; Uchida T; Kimura K; Yamada Y
Biol Pharm Bull; 2018; 41(2):153-157. PubMed ID: 29386477
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
Abe M; Higuchi T; Moriuchi M; Okamura M; Tei R; Nagura C; Takashima H; Kikuchi F; Tomita H; Okada K
Diabetes Res Clin Pract; 2016 Jun; 116():244-52. PubMed ID: 27321342
[TBL] [Abstract][Full Text] [Related]
13. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
Boulton DW
Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Koska J; Sands M; Burciu C; Reaven P
Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
[TBL] [Abstract][Full Text] [Related]
16. Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Gibbs JP; Fredrickson J; Barbee T; Correa I; Smith B; Lin SL; Gibbs MA
J Clin Pharmacol; 2012 Oct; 52(10):1494-505. PubMed ID: 22162539
[TBL] [Abstract][Full Text] [Related]
17. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
Ndefo UA; Okoli O; Erowele G
Am J Health Syst Pharm; 2014 Jan; 71(2):103-9. PubMed ID: 24375601
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes.
Anderson R; Hayes J; Stephens JW
Expert Opin Drug Metab Toxicol; 2016; 12(4):467-73. PubMed ID: 26878666
[TBL] [Abstract][Full Text] [Related]
19. DPP-4 inhibitors: what may be the clinical differentiators?
Gerich J
Diabetes Res Clin Pract; 2010 Nov; 90(2):131-40. PubMed ID: 20708812
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of drug efficacy of DPP-4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics.
Takayanagi R; Uchida T; Kimura K; Yamada Y
Biopharm Drug Dispos; 2017 May; 38(4):273-279. PubMed ID: 27976813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]